Ongoing Randomized Studies of Selinexor - Selinexor with chemotherapy, single-agent activity, etc
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses ongoing randomized studies of Selinexor and Selinexor with chemotherapy, single-agent activity, etc at the 2017 American Society...
Author: ASHReport
Added: 01/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Successor Trials from North American and European Group - Testing imatnib with chemotherapy backbones
Stephen Hunger, MD from Children's Hospital of Philadelphia discusses successor trials from North American and European group and testing imatnib with chemotherapy backbones at the 2017 American Socie...
Author: ASHReport
Added: 01/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2018 Category: Cancer & Oncology Source Type: podcasts
EsPhALL Regimen - Adding Dasatnib to Intensive Chemotherapy Backbone
Stephen Hunger, MD from Children's Hospital of Philadelphia discusses EsPhALL regimen and adding Dasatnib to intensive chemotherapy backbone at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Chemo-Immunotherapy in Non-Squamous NSCLC: Has the KEYNOTE-189 Trial Defined a Clear Standard of Care? (BMIC-022)
Dr. Jack West reviews the results and pending questions of the KEYNOTE-189 trial of chemotherapy with or without pembrolizumab (KEYTRUDA) as first line therapy for advanced non-squamous NSCLC, as well...
Author: BeaconMedIC
Added: 01/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Should standard chemotherapy regimens be altered in favor of small molecules? iFCG for frontline CLL
With many promising novel therapeutic agents exiting pharmaceutical pipelines, a question that arises is whether standard chemotherapy regimens with long-term data should be shunned or altered in favo...
Author: VJHemOnc
Added: 01/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Small molecule-chemotherapy combinations: ibrutinib plus rituximab for CLL
Antibody-chemotherapy combinations are a standard treatment for hematological malignancies, and with an increase in small molecules coming through the pharmaceutical pipeline, the question is now will...
Author: VJHemOnc
Added: 01/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Should standard chemotherapy regimens be altered in favor of small molecules? iFCG for frontline CLL
With many promising novel therapeutic agents exiting pharmaceutical pipelines, a question that arises is whether standard chemotherapy regimens with long-term data should be shunned or altered in favo...
Author: VJOncology
Added: 01/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Small molecule-chemotherapy combinations: ibrutinib plus rituximab for CLL
Antibody-chemotherapy combinations are a standard treatment for hematological malignancies, and with an increase in small molecules coming through the pharmaceutical pipeline, the question is now will...
Author: VJOncology
Added: 01/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 16, 2018 Category: Cancer & Oncology Source Type: podcasts
The new chemotherapy combination works better than previous - Information to be disseminated soon, awaits approval by regulators
Joseph M. Connors, MD from British Colombia Cancer Agency discusses the new chemotherapy combination works better than previous and information to be disseminated soon, awaits approval by regulators a...
Author: ASHReport
Added: 01/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2018 Category: Cancer & Oncology Source Type: podcasts
neoadjuvant treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival.
Although data indicate that the first rationale remains valid,... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Neoadjuvent treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival.
Although data indicate that the first rationale remains valid,... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
neoadjuvant treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival.
Although data indicate that the first rationale remains valid, the others have not led to the desired outcomes. More conservative surgery after neoadjuvant chemotherapy can result in a higher rate of local recurrence, and, despite the earlier initiation of systemic treatment, no improvement in sur vival has been seen.
Jayant Vaidya, profess...
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
neoadjuvant treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival.
Although data indicate that the first rationale remains valid,... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
neoadjuvant treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival.
Although data indicate that the first rationale remains valid, the others have not led to the desired outcomes. More conservative surgery after neoadjuvant chemotherapy can result in a higher rate of local recurrence, and, despite the earlier initiation of systemic treatment, no improvement in survival has been seen.
Jayant Vaidya, professor...
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ Group Source Type: podcasts
